Jeil Pharmaceutical Co Ltd (271980) — Cash Flow-to-Debt Ratio
Jeil Pharmaceutical Co Ltd (271980) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of ₩13.23 Billion could theoretically repay 0% of its total liabilities (₩258.07 Billion) in one year. Explore Jeil Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jeil Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Jeil Pharmaceutical Co Ltd across 8 annual periods. Also explore Jeil Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Jeil Pharmaceutical Co Ltd (2017–2024)
Year-by-year debt coverage analysis for Jeil Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Jeil Pharmaceutical Co Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.01x | ₩3.21 Billion | ₩306.38 Billion | ▲ +169.5% |
| 2023 | -0.02x | ₩-4.98 Billion | ₩330.29 Billion | ▲ +70.0% |
| 2022 | -0.05x | ₩-15.15 Billion | ₩301.29 Billion | ▼ -168.2% |
| 2021 | 0.07x | ₩19.10 Billion | ₩259.14 Billion | ▲ +191.8% |
| 2020 | -0.08x | ₩-19.05 Billion | ₩237.18 Billion | ▼ -164.2% |
| 2019 | 0.13x | ₩28.96 Billion | ₩231.54 Billion | ▲ +27.1% |
| 2018 | 0.10x | ₩21.45 Billion | ₩217.97 Billion | ▲ +651.2% |
| 2017 | -0.02x | ₩-4.21 Billion | ₩235.74 Billion | — |